- |||||||||| Tepezza (teprotumumab) / Roche, Amgen
Rationale for Targeting Insulin-like Growth Factor Signalling in Systemic Sclerosis (Poster Hall; in person) - Sep 23, 2023 - Abstract #ACRConvergence2023ACR_Convergence_3062;
Attenuation of hallmark profibrotic gene and protein signature in explant dermal SSc fibroblasts by teprotumumab is consistent with autocrine or paracrine activation of SSc fibroblasts by IGF1 or IGF2 via IGF1-R.Our findings are consistent with an antifibrotic effect and support clinical evaluation of teprotumumab as a possible therapy in SSc. Figure 1 IGF ligand and receptor levels in SSc or control serum Figure 2 Effect of teprotumumab on protein and mRNA expression in SSc and HC fibroblasts
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
TEPROTUMUMAB IN EUTHYROID EYE DISEASE AND SUCCESSFUL MANAGEMENT OF DEBILITATING MUSCLE SPASMS () - Sep 20, 2023 - Abstract #ATA2023ATA_444;
We also propose management of this untoward side effect with adequate hydration and consideration of an alternative dosing schedule. Lastly, our case supports the use of TSI as a biomarker of TED activity (3) and suggests its use for therapy response in euthyroid patients.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Enrollment closed: TEPEZZA (clinicaltrials.gov) - Sep 7, 2023
P3b/4, N=313, Active, not recruiting,
While additional research is needed as to the cause of severe hyperglycemia in select patients, providers should consider proactively monitoring glucose throughout treatment with teprotumumab by ensuring that patients have baseline labs and labs at every visit and access to a glucometer with education for its use. Recruiting --> Active, not recruiting
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Teprotumumab-related Cutaneous Hypersensitivity Reactions. (Pubmed Central) - Sep 1, 2023
The onset of the cutaneous hypersensitivity reaction was also observed during the treatment course in all cases, between the second and fifth infusions. Teprotumumab-related cutaneous reactions suggest a possible immunogenic component of the monoclonal antibody and highlight the importance of close monitoring during treatment.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Efficacy of teprotumumab therapy in patients with long-duration thyroid eye disease. (Pubmed Central) - Aug 23, 2023
Teprotumumab-related cutaneous reactions suggest a possible immunogenic component of the monoclonal antibody and highlight the importance of close monitoring during treatment. Teprotumumab may be an appropriate treatment for TED regardless of disease duration and irrespective of the presence or absence of markers of active inflammation within the orbit.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Review, Journal: The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials. (Pubmed Central) - Aug 21, 2023
In summary, teprotumumab demonstrated greater improvement in proptosis response, proptosis, diplopia response, overall response, GO-QOL, and CAS. Nonetheless, it should be considered that its use is associated with a higher risk of adverse events.
- |||||||||| Tepezza (teprotumumab) / Roche, Amgen
Impact of Teprotumumab on Strabismus Due to Thyroid Eye Disease (WEST 2005) - Aug 21, 2023 - Abstract #AAO2023AAO_1238;
Nonetheless, it should be considered that its use is associated with a higher risk of adverse events. Cosponsored by the American Association for Pediatric Ophthalmology and Strabismus (AAPOS)
- |||||||||| Tepezza (teprotumumab) / Roche, Amgen
Teprotumumab (WEST 3018) - Aug 21, 2023 - Abstract #AAO2023AAO_828;
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
The Use of Medical Therapy for Thyroid Eye Disease in the Era of Teprotumumab () - Aug 16, 2023 - Abstract #ATA2023ATA_250;
However, this did not translate into every evaluated patient receiving the recommended medical treatment, mainly due to safety concerns and accessibility of the medication. Efforts to address these challenges should focus on the identification of risk factors for adverse effects and health care policy adjustments.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche, Actemra IV (tocilizumab) / Roche, JW Pharma
Journal: Medical Therapy in Patients with Moderate to Severe, Steroid-resistant, Thyroid Eye Disease. (Pubmed Central) - Jul 29, 2023
Additionally, the teprotumumab cases demonstrated similar improvement in proptosis and diplopia to the teprotumumab controls. Further evaluation, particularly regarding long term response and side-effect profile, of these medications in steroid-resistant TED is needed.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche, Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Retrospective data, Review, Journal: Monoclonal antibodies for the treatment of Graves' ophthalmopathy: A systematic review and meta-analysis. (Pubmed Central) - Jul 26, 2023
This meta-analysis demonstrated that monoclonal antibodies were associated with more favorable clinical outcomes than standard steroid therapy or placebo, especially with regard to CAS, change in proptosis, diplopia, and QoL, with teprotumumab being superior. In addition, only minor safety concerns were identified with monoclonal antibodies though less worrisome than using traditional steroids.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: The Challenges and Therapeutic Prospects in Eye Disease. (Pubmed Central) - Jun 28, 2023
No abstract available A number of key insights into eye disease have been revealed in the past decade, which has resulted in the development of novel, effective, targeted therapies such as teprotumumab for the treatment of thyroid eye disease (also known as Graves' orbitopathy) [...].
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Thyroid Eye Disease (TED): Early Diagnosis, Referral, and Treatment with TEPEZZA (Expo Theater) - Jun 22, 2023 - Abstract #ATA2023ATA_73;
A number of key insights into eye disease have been revealed in the past decade, which has resulted in the development of novel, effective, targeted therapies such as teprotumumab for the treatment of thyroid eye disease (also known as Graves' orbitopathy) [...]. Sponsored by Horizon
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Teprotumumab in thyroid eye disease: wonder drug or great divider? (Pubmed Central) - Jun 14, 2023
Professional organisations have an important role addressing these problems. Future studies need to focus on optimising the measurement of outcomes and on assessing cost-effectiveness.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Teprotumumab in Unexplored Presentation of Thyroid Eye Disease (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_2169;
He received radioactive iodine (RAI) for treatment of GD after failure to Methimazole therapy...He was discharged home with oral prednisone taper down until it was discontinued 6 months later with mild improvement of symptoms...This case describes the positive effects of teprotumumab in a patient with characteristics not previously studied such as active TED of longer duration than in clinical trials, previous treatment with orbital surgery or > 1g of methylprednisolone equivalent therapy, and increased IOP. Rather than drawing conclusions, our goal is to create awareness and promote further research of teprotumumab and novel agents in patients with TED with previously uncharacterized presentations as it may have important implications for their management including significant improvement in their quality of life.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Pretibial Myxedema Associated With Hashimoto Thyroiditis Treated With Teprotumumab (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_2151;
In TED, TSI binds to IGF-1R creating a complex that promotes orbital inflammation. Teprotumumab is believed to degrade antibody-receptor complex and downregulate fibroblast activation and glycosaminoglycans deposition.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Orbitopathy as the Sole Manifestation of Hashimoto's Thyroiditis in a Euthyroid Patient: A Case Report (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_2149;
Treatment with teprotumumab infusion was started with improvement in the patient's symptoms.CASE Usually mild eye symptoms are seen in Hashimoto's thyroiditis such as dryness, blurred vision, upper eyelid retraction and loss of lateral third of eyebrows...This case sheds the light on exophthalmos being an atypical presentation of Hashimoto's thyroiditis in a clinically and biochemically euthyroid patient. Physicians should be cognizant of this rare manifestation for prompt recognition and early treatment which can prevent corneal involvement and blindness due to optic nerve compression.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Hearing-Related Adverse Events in Teprotumumab Oncology Clinical Trials (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_1650;
The most severe events reported were at higher drug exposures than used in the TED clinical trials. The types of AEs and incidence were also comparable to those reported in the TED clinical trial program and as reported in the current FDA-approved prescribed labeling for teprotumumab in the United States.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Hearing-related Issues Associated with Graves' Disease, Thyroid Eye Disease and Treatment with Teprotumumab (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_1640;
Therefore, it is important to assess the history of hearing-related issues in pts with thyroid autoimmunity before ascribing hearing-related changes in those treated with teprotumumab. Further, well-controlled research is needed to document incrementally increased risk of hearing-related AEs in pts with TED who receive teprotumumab.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
A Randomized, Quadruple-masked, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Teprotumumab in Patients with Chronic (Inactive/Low CAS) Thyroid Eye Disease (ENDOExpo) - May 11, 2023 - Abstract #ENDO2023ENDO_1634;
P4
Among EU patients with TED, teprotumumab resulted in better outcomes with respect to proptosis, CAS, diplopia, and quality of life as compared with placebo. Despite a long duration of TED and low "activity", patients enrolled in this trial have high levels of proptosis and impaired quality of life at baseline.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Review, Journal: Graves' Disease in Children: An Update. (Pubmed Central) - May 8, 2023
Management recommendations include the first-line use of a prolonged course of ATDs for at least 3?years and potentially 5?years or more. Rituximab and Teprotumumab are new novel alternative medications for the treatment of adult patients with GD and Graves' orbitopathy respectively, but evidence of the efficacy and safety of these drugs in pediatric patients with GD is lacking.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal, Adverse events: Prospective Assessment of Otologic Adverse Events due to Teprotumumab: Preliminary Results. (Pubmed Central) - Mar 21, 2023
In our cohort, a high incidence of otologic symptoms was found to be associated with teprotumumab usage. Subjective hearing decline, changes in ultrahigh-frequency hearing as well as eustachian tube dysfunction may be encountered and suggest the potential ototoxicity of teprotumumab.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Teprotumumab-related hyperglycemia. (Pubmed Central) - Mar 13, 2023
Hyperglycemia may persist after stopping teprotumumab. These findings underscore the importance of guidelines for screening and management of teprotumumab-related hyperglycemia.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Teprotumumab for the treatment of thyroid eye disease. (Pubmed Central) - Mar 9, 2023
Teprotumumab was approved by the FDA on 21 January 2020 for the treatment of TED. For the above-mentioned reasons teprotumumab represents a potential first line therapy for TED that could replace the use of steroids in the next future.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Outcomes of Patients With Thyroid Eye Disease Partially Treated With Teprotumumab. (Pubmed Central) - Mar 7, 2023
For the above-mentioned reasons teprotumumab represents a potential first line therapy for TED that could replace the use of steroids in the next future. Patients partially treated with teprotumumab achieve significant reduction in proptosis, CAS, and extraocular muscle restriction and maintain these improvements through the period of interruption.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche
Journal: Reduction of Teprotumumab-Induced Hearing Loss With Comparable Efficacy Using Half-Dose Therapy. (Pubmed Central) - Mar 7, 2023
She tolerated all infusions with an overall reduction in the severity of her adverse events and without return of significant sensorineural hearing loss. The authors conclude that a lower dose of teprotumumab can be effective for patients with active moderate-severe thyroid eye disease who experience significant or intolerable adverse events.
- |||||||||| Clinical, Journal: Monoclonal Antibodies for the Treatment of Graves Orbitopathy: Precision Medicine? (Pubmed Central) - Feb 3, 2023
This review aims to effectively describe the pathogenesis of GO from the perspective of target cells and target antigens and provide ideas for its fundamental treatment. Considering the lack of head-to-head comparisons between Mabs, the relapse rate, the possibility of severe collateral effects, and the cost of Mabs, it is not clear which Mab is the safest and most useful to treat GO.
- |||||||||| Tepezza (teprotumumab) / Horizon Therapeutics, Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Journal: A rare case of severe bilateral Graves' orbitopathy involving an anophthalmic socket. (Pubmed Central) - Jan 11, 2023
Patients with severe GO in an only seeing-eyed patient should be referred early to a multidisciplinary Joint Thyroid Eye clinic for expert review and management. Patient outcomes including sight loss are likely to be improved by the extended range of medical and surgical treatment modalities available at specialist clinics treating GO, including the use of immunomodulatory drugs like rituximab or teprotumumab.
|
